{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T02:35:41Z","timestamp":1774924541803,"version":"3.50.1"},"reference-count":79,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","id.theclinics.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.idc.2015.10.003","type":"journal-article","created":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T11:01:27Z","timestamp":1451386887000},"page":"265-275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Contemporary Strategies in the Prevention and Management of Fungal Infections"],"prefix":"10.1016","volume":"30","author":[{"given":"Philipp","family":"Koehler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.idc.2015.10.003_bib1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ijantimicag.2013.09.005","article-title":"Nosocomial bloodstream infections due to Candida spp. in the USA: species distribution, clinical features and antifungal susceptibilities","volume":"43","author":"Wisplinghoff","year":"2014","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10.1016\/j.idc.2015.10.003_bib2","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/myc.12081","article-title":"Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study","volume":"56","author":"Lewis","year":"2013","journal-title":"Mycoses"},{"issue":"1","key":"10.1016\/j.idc.2015.10.003_bib3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1128\/CMR.00029-06","article-title":"Epidemiology of invasive candidiasis: a persistent public health problem","volume":"20","author":"Pfaller","year":"2007","journal-title":"Clin Microbiol Rev"},{"issue":"11","key":"10.1016\/j.idc.2015.10.003_bib4","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.2165\/00003495-200767110-00004","article-title":"Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients","volume":"67","author":"Maschmeyer","year":"2007","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.idc.2015.10.003_bib5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/CCM.0b013e318236f297","article-title":"Systemic antifungal therapy in critically ill patients without invasive fungal infection*","volume":"40","author":"Azoulay","year":"2012","journal-title":"Crit Care Med"},{"issue":"5","key":"10.1016\/j.idc.2015.10.003_bib6","doi-asserted-by":"crossref","first-page":"492.e1","DOI":"10.1016\/j.cmi.2015.01.013","article-title":"Antifungal stewardship in a tertiary-care institution: a bedside intervention","volume":"21","author":"Valerio","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.idc.2015.10.003_bib7","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12879-015-0809-z","article-title":"How much European prescribing physicians know about invasive fungal infections management?","volume":"15","author":"Valerio","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2015.10.003_bib8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/510393","article-title":"Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship","volume":"44","author":"Dellit","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2015.10.003_bib9","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.clinthera.2015.03.021","article-title":"Economic comparison of an empirical versus diagnostic-driven strategy for treating invasive fungal disease in immunocompromised patients","volume":"37","author":"Barnes","year":"2015","journal-title":"Clin Ther"},{"issue":"9","key":"10.1016\/j.idc.2015.10.003_bib10","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00134-015-3866-2","article-title":"A\u00a0multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality","volume":"41","author":"Bassetti","year":"2015","journal-title":"Intensive Care Med"},{"issue":"Suppl 7","key":"10.1016\/j.idc.2015.10.003_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients","volume":"18","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.idc.2015.10.003_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12831","article-title":"Mechanisms of echinocandin antifungal drug resistance","volume":"1354","author":"Perlin","year":"2015","journal-title":"Ann N Y Acad Sci"},{"issue":"Suppl 7","key":"10.1016\/j.idc.2015.10.003_bib13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/1469-0691.12041","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)","volume":"18","author":"Ullmann","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"13","key":"10.1016\/j.idc.2015.10.003_bib14","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJM199203263261301","article-title":"A\u00a0controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation","volume":"326","author":"Goodman","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.idc.2015.10.003_bib15","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood.V96.6.2055","article-title":"Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial","volume":"96","author":"Marr","year":"2000","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.idc.2015.10.003_bib16","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/infdis\/171.6.1545","article-title":"Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation\u2013a prospective, randomized, double-blind study","volume":"171","author":"Slavin","year":"1995","journal-title":"J\u00a0Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2015.10.003_bib17","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood-2003-08-2644","article-title":"Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants","volume":"103","author":"Marr","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.idc.2015.10.003_bib18","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1046\/j.1365-2141.1999.01465.x","article-title":"A\u00a0randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group","volume":"105","author":"Morgenstern","year":"1999","journal-title":"Br J Haematol"},{"issue":"24","key":"10.1016\/j.idc.2015.10.003_bib19","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","article-title":"Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation","volume":"116","author":"Wingard","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.idc.2015.10.003_bib20","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2015.10.003_bib21","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.idc.2015.10.003_bib22","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2015.10.003_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/civ707","article-title":"A\u00a0randomized, placebo-controlled trial of pre-emptive antifungal therapy for the prevention of invasive candidiasis following gastrointestinal surgery for intra-abdominal infections","author":"Knitsch","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2015.10.003_bib24","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00134-005-2571-y","article-title":"Candida spp. colonization significance in critically ill medical patients: a prospective study","volume":"31","author":"Charles","year":"2005","journal-title":"Intensive Care Med"},{"issue":"4","key":"10.1016\/j.idc.2015.10.003_bib25","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jhin.2014.11.006","article-title":"Preventing invasive candida infections. Where could we do better?","volume":"89","author":"Eggimann","year":"2015","journal-title":"J\u00a0Hosp Infect"},{"issue":"3","key":"10.1016\/j.idc.2015.10.003_bib26","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/01.CCM.0000202208.37364.7D","article-title":"A\u00a0bedside scoring system (\u201cCandida score\u201d) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization","volume":"34","author":"Leon","year":"2006","journal-title":"Crit Care Med"},{"issue":"4","key":"10.1016\/j.idc.2015.10.003_bib27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10096-007-0270-z","article-title":"Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting","volume":"26","author":"Ostrosky-Zeichner","year":"2007","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2015.10.003_bib28","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/13693780410001731619","article-title":"Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials","volume":"43","author":"Paphitou","year":"2005","journal-title":"Med Mycol"},{"issue":"5","key":"10.1016\/j.idc.2015.10.003_bib29","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/INF.0b013e3181da2171","article-title":"A\u00a0randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia","volume":"29","author":"Maertens","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"14","key":"10.1016\/j.idc.2015.10.003_bib30","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.idc.2015.10.003_bib31","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group","volume":"340","author":"Walsh","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.idc.2015.10.003_bib32","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.idc.2015.10.003_bib33","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1086\/520980","article-title":"Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis","volume":"45","author":"Pappas","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"24","key":"10.1016\/j.idc.2015.10.003_bib34","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"9572","key":"10.1016\/j.idc.2015.10.003_bib35","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(07)60605-9","article-title":"Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial","volume":"369","author":"Kuse","year":"2007","journal-title":"Lancet"},{"issue":"Suppl 7","key":"10.1016\/j.idc.2015.10.003_bib36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/1469-0691.12038","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures","volume":"18","author":"Cuenca-Estrella","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.idc.2015.10.003_bib37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1086\/504810","article-title":"Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study","volume":"43","author":"Garey","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.idc.2015.10.003_bib38","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1086\/378745","article-title":"Attributable mortality of nosocomial candidemia, revisited","volume":"37","author":"Gudlaugsson","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2015.10.003_bib39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10096-002-0854-6","article-title":"Duration of antifungal treatment and development of delayed complications in patients with candidaemia","volume":"22","author":"Oude Lashof","year":"2003","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2015.10.003_bib40","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0002-9343(02)01248-2","article-title":"Effects of nosocomial candidemia on outcomes of critically ill patients","volume":"113","author":"Blot","year":"2002","journal-title":"Am J Med"},{"issue":"9","key":"10.1016\/j.idc.2015.10.003_bib41","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1128\/AAC.49.9.3640-3645.2005","article-title":"Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality","volume":"49","author":"Morrell","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2015.10.003_bib42","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1128\/AAC.00945-09","article-title":"Effect of antifungal therapy timing on mortality in cancer patients with candidemia","volume":"54","author":"Taur","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 3","key":"10.1016\/j.idc.2015.10.003_bib43","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/1469-0691.12360","article-title":"ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections","volume":"20","author":"Arendrup","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 7","key":"10.1016\/j.idc.2015.10.003_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1469-0691.12037","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases","volume":"18","author":"Ullmann","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"20","key":"10.1016\/j.idc.2015.10.003_bib45","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1056\/NEJM199411173312001","article-title":"A\u00a0randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute","volume":"331","author":"Rex","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.idc.2015.10.003_bib46","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/clinids\/23.5.964","article-title":"Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature","volume":"23","author":"Anaissie","year":"1996","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.idc.2015.10.003_bib47","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/myc.12207","article-title":"Our 2014 approach to candidaemia","volume":"57","author":"Koehler","year":"2014","journal-title":"Mycoses"},{"issue":"8","key":"10.1016\/j.idc.2015.10.003_bib48","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/cid\/cis021","article-title":"Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials","volume":"54","author":"Andes","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2015.10.003_bib49","doi-asserted-by":"crossref","first-page":"e821","DOI":"10.1111\/j.1439-0507.2011.02036.x","article-title":"Efficacy of anidulafungin against biofilms of different Candida species in long-term trials of continuous flow cultivation","volume":"54","author":"Bernhardt","year":"2011","journal-title":"Mycoses"},{"issue":"6","key":"10.1016\/j.idc.2015.10.003_bib50","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1128\/AAC.46.6.1773-1780.2002","article-title":"Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins","volume":"46","author":"Kuhn","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idc.2015.10.003_bib51","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00277-014-2108-y","article-title":"Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology","volume":"93","author":"Tacke","year":"2014","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.idc.2015.10.003_bib52","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-2141.2011.08838.x","article-title":"Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation","volume":"155","author":"Marks","year":"2011","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.idc.2015.10.003_bib53","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.bbmt.2012.03.014","article-title":"Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant","volume":"18","author":"Huang","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.idc.2015.10.003_bib54","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12879-015-0855-6","article-title":"Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients","volume":"15","author":"Bow","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"10","key":"10.1016\/j.idc.2015.10.003_bib55","doi-asserted-by":"crossref","first-page":"5758","DOI":"10.1128\/AAC.03050-14","article-title":"Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia","volume":"58","author":"Duarte","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.idc.2015.10.003_bib56","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.idc.2015.10.003_bib57","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/597395","article-title":"Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial","volume":"48","author":"Cordonnier","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2015.10.003_bib58","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1086\/605665","article-title":"Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO)","volume":"49","author":"Girmenia","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.idc.2015.10.003_bib59","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1086\/496927","article-title":"Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study","volume":"41","author":"Maertens","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2015.10.003_bib60","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/bmt.2008.355","article-title":"A\u00a0prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT","volume":"43","author":"Hebart","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.idc.2015.10.003_bib61","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3324\/haematol.2011.042598","article-title":"The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project","volume":"96","author":"Pagano","year":"2011","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.idc.2015.10.003_bib62","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/cid\/ciu833","article-title":"Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based Aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: a randomized controlled trial","volume":"60","author":"Aguado","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2015.10.003_bib63","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.idc.2015.10.003_bib64","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2015.10.003_bib65","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/jac\/dkp355","article-title":"An EORTC phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients","volume":"64","author":"Viscoli","year":"2009","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.idc.2015.10.003_bib66","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/bmt.2009.334","article-title":"Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: a European Organisation for Research and Treatment of Cancer study","volume":"45","author":"Herbrecht","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.idc.2015.10.003_bib67","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1128\/AAC.05134-11","article-title":"Phase II dose escalation study of caspofungin for invasive Aspergillosis","volume":"55","author":"Cornely","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2015.10.003_bib68","unstructured":"US Food and Drug Administration. Isavuconazonium\u2014invasive aspergillosis and invasive mucormycosis. Advisory Committee Briefing Document 2015. Available at: www.FDAgov\/downloads\/advisory committees\/committeesmeetingmaterials\/drugs\/anti-infectivedrugs advisorycommittee\/ucm430748pdf. Accessed August 16, 2015."},{"issue":"5","key":"10.1016\/j.idc.2015.10.003_bib69","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2217\/fmb.15.34","article-title":"Isavuconazole: a new extended spectrum triazole for invasive mold diseases","volume":"10","author":"Ananda-Rajah","year":"2015","journal-title":"Future Microbiol"},{"issue":"7","key":"10.1016\/j.idc.2015.10.003_bib70","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s40265-015-0398-6","article-title":"Isavuconazonium: first global approval","volume":"75","author":"McCormack","year":"2015","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.idc.2015.10.003_bib71","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/civ571","article-title":"Isavuconazole: a new broad-spectrum triazole antifungal agent","volume":"61","author":"Miceli","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"Suppl 3","key":"10.1016\/j.idc.2015.10.003_bib72","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/1469-0691.12371","article-title":"ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013","volume":"20","author":"Cornely","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.idc.2015.10.003_bib73","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/0003-4975(94)90243-7","article-title":"Pulmonary mucormycosis: results of medical and surgical therapy","volume":"57","author":"Tedder","year":"1994","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"10.1016\/j.idc.2015.10.003_bib74","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/AAC.50.1.126-133.2006","article-title":"Posaconazole as salvage therapy for zygomycosis","volume":"50","author":"Greenberg","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.idc.2015.10.003_bib75","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1086\/500212","article-title":"Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases","volume":"42","author":"van Burik","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2015.10.003_bib76","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3109\/1040841X.2012.711741","article-title":"Mucormycosis treated with posaconazole: review of 96 case reports","volume":"39","author":"Vehreschild","year":"2013","journal-title":"Crit Rev Microbiol"},{"issue":"10","key":"10.1016\/j.idc.2015.10.003_bib77","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.3324\/haematol.2012.083063","article-title":"Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries","volume":"98","author":"Pagano","year":"2013","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.idc.2015.10.003_bib78","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/myc.12319","article-title":"Our 2015 approach to invasive pulmonary aspergillosis","volume":"58","author":"Liss","year":"2015","journal-title":"Mycoses"},{"issue":"9","key":"10.1016\/j.idc.2015.10.003_bib79","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/myc.12203","article-title":"Our 2014 approach to mucormycosis","volume":"57","author":"Tacke","year":"2014","journal-title":"Mycoses"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552015000926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552015000926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T09:11:45Z","timestamp":1599988305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552015000926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0891552015000926"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2015.10.003","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contemporary Strategies in the Prevention and Management of Fungal Infections","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2015.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}